Attorney Docket No. 06171.105005



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Gosselin, et al.

Serial No.:

10/022,276

Filed:

Title:

14-Dec-2001

B-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B Virus

Assistant Commissioner for Patents Washington, DC 20231

Group Art Unit: 1623

Examiner: L. Eric Crane

August 23, 2002

Transmittal of Information Disclosure Statement

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publications listed on the accompanying PTO-1449. Copies of all listed references are enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

If the Examiner determines a fee is required, the Commissioner is authorized to charge any requisite fees associated with this paper to Deposit Account No. 11-0980.

Respectfully submitted,

Reg. No. 48,30

KING & SPALDING 191 Peachtree Street Atlanta, GA 30303 404-572-2882 (Telephone) 404-572-5145 (Facsimile)





INFORMATION DISCLOSURE STATEMENT Docket No. 06171.105005
10/022,276

RECEIVER 1600/2000
FECH CENTER 1600/2000

CERTIFICATE OF MAILING

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as Express Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: August 23, 2002